Skip to main content

Table 2 Principal demographic and hepato-virological data of the 14 HCV-positive patients with mixed cryoglobulinemia before and 3 months after treatment with rituximab

From: Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment

Parameter Baseline 3 months Normal range P value
Age (years) 60.43 ± 43   Normal range  
Gender (M%) 28.5    
BMI 26.24 ± 1.74   18–25  
Platelets (×109 /L) 145.50 ± 71.22 163.4 ± 19.89 140–440 p = 0.03
RBC (×1012 /L) 4255 ± 438 4369 ± 723 4200–5400 p = 0.11
WBC (×109 /L) 4684 ± 1374 4829 ± 1898 4–10 p = 0.86
ALT (U/L) 64.09 ± 39.66 65.63 ± 35.92 5–40 p = 0.86
AST (U/L) 69.54 ± 56.60 74.81 ± 40.78 5–40 p = 0.08
GGT (U/L) 66.09 ± 94.47 47.09 ± 30.03 10–40 p = 0.38
Creatinine (mg/dL) 0.70 ± 0.19 0.65 ± 0.15 0.6–1.5 p = 0.40
Glucose (mg/dL) 92.66 ± 11.58 92.33 ± 6.12 65–110 p = 0.32
Albumine (g/dL) 3.82 ± 0.35 4.05 ± 0.41 3.5–5.0 p = 0.02
Bilirubin (mg/dL) 0.88 ± 0.55 1.53 ± 1.99 0,3–1 p = 0.13
HCV-RNA (UI/L) 719798 ± 677364 1469311 ± 1576236 Undetectable p = 0.07
Genotype 1 11    
Genotype 2a/2c 2    
Genotype 3 1    
CC polymorfism of IL-28-β 27.27%    
Mean stiffness (kPa) 20.44 ± 17.29 17.00 ±16.05   p = 0.03
CD 19+ (106 L) 124.2 ± 56.15 38 ± 16.59   p = 0.04
  1. Abbreviations: BMI Body mass index, RBC Red blood cells, WBC White blood cells, ALT Alanine transaminase, AST Aspartate aminotransferase, GGT Gamma glutamyl-transpeptidase. Statistically significant p values are labeled with bold text.